Short answer
Paysign, Inc. (PAYS) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $22M (up 41.6% year over year) with net income of $2M.
Q3 2025 key financials · XBRL
- Revenue
- $22M
- +41.6% YoY · +13.2% QoQ
- Net income
- $2M
- +54.2% YoY · +59.6% QoQ
- Operating margin
- 7.3%
- Gross margin
- 56.3%
- EPS (diluted)
- $0.03
- +50.0% YoY · +50.0% QoQ
Source: XBRL data from the Paysign, Inc. (PAYS) Q3 2025 10-Q on SEC EDGAR. USD.
Paysign, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $21.6M, up 41.6% YoY from $15.3M
- Pharma revenue $7.9M, up 141.9%; plasma revenue $12.9M, up 12.4%
- Gross margin 56.3% vs 55.5%; net margin 10.3% vs 9.4% YoY
- Gross dollar volume $552M vs $456M; pharma added 39 programs and plasma added 117 centers
- 2025 investment focus: technology, sales, cybersecurity, fraud, customer service, and compliance
Risk Factors
- No quarterly risk-factor update; Paysign qualifies as a smaller reporting company and omitted Item 1A disclosure
- No new regulatory, legal, or compliance risk disclosed in the provided section
- Rule 10b5-1 arrangements adopted by four executives, covering 805 thousand shares
- Share-repurchase authorization remaining: $3,001,285 as of September 30, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Paysign, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.